Loading clinical trials...
Loading clinical trials...
Phase II Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Bioactivity in Patients With Sporadic Colorectal Adenomas and With Colorectal Cancer
Conditions
Interventions
Linaclotide
Placebo
Locations
3
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
VA Puget Sound Health Care Sysem
Seattle, Washington, United States
Start Date
October 30, 2019
Primary Completion Date
June 30, 2026
Completion Date
June 30, 2026
Last Updated
April 2, 2026
NCT06133387
NCT07035691
NCT06452745
NCT05144152
NCT06205862
NCT05638542
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions